Meta-analysis of clinical efficacy and safety of the treatment of impaired glucose tolerance by Tianqijiangtang Capsule

摘要

Abstract Objective: To evaluate the clinical efficacy and safety of Tianqijiangtang Capsule (TG) during the treatment of impaired glucose tolerance (IGT). Methods: With Chinese words of “impaired glucose tolerance, abnormal glucose tolerance, IGT” and “TG” as search terms, China National Knowledge Infrastructure, VIP, Wanfang Data and Pubmed were searched up from database inception until October 2017. All the controlled clinical research concerning the treatment of impaired glucose tolerance by TG meeting the inclusion and exclusion criteria were retrieved and analyzed by Review Manager 5.3 software provided by Cochrane cooperation Network. Results: A total of 7 articles including 1082 participants were enrolled. Meta-analysis showed that the OR value of inversion rate was 2.17, 95% CI (1.65, 2.84). WMD value of fasting plasma glucose was -0.25, 95% CI (-0.39, -0.11). After 2 h on empty stomach, the WMD value of serum glucose was -0.73, 95% CI (-0.96, -0.51), all of which were better than these of control group. The OR value of progression rate (type 2 diabetes mellitus) was 0.44, 95% CI (0.32, 0.59), less than the control group. All of the differences were statistically significant. No hepatic and renal toxicity case was reported. Only 1 article reported adverse reactions in the course of treatment. Conclusion: TG could treat IGT effectively, delay and even invert the progress of IGT, but its security still needed further discussion.